Restoration of peripheral blood natural killer and B cell levels in patients affected by rheumatoid and psoriatic arthritis during etanercept treatment

Conigliaro, Paola; Triggianese, Paola; Perricone, Carlo; Chimenti, Maria Sole; Muzio, G Di; Ballanti, Eleonora; Guarino, Maria Domenica; Kröegler, B.; Gigliucci, Gianfranco; Grelli, Sandro; Perricone, Roberto

doi:10.1111/cei.12335

Cited by 49 publications

(33 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, in the clinical practice they are subject to the same treatment options. Hopefully, these findings will be the object of future and larger studies, in line with recent interest in exploring the effects of various anti‐rheumatic drugs, including biologicals, on immune functions in various rheumatological conditions .…”

Section: Discussionmentioning

confidence: 72%

Serum thymosin α 1 levels in patients with chronic inflammatory autoimmune diseases

Pica¹,

Chimenti

Gaziano³

et al. 2016

Clinical and Experimental Immunology

Self Cite

View full text Add to dashboard Cite

Thymosin alpha 1 (Tα1) is a powerful modulator of immunity and inflammation. Despite years of studies, there are a few reports evaluating serum Tα1 in health and disease. We studied a cohort of healthy individuals in comparison with patients affected by chronic inflammatory autoimmune diseases. Sera from 120 blood donors (healthy controls, HC), 120 patients with psoriatic arthritis (PsA), 40 with rheumatoid arthritis (RA) and 40 with systemic lupus erythematosus (SLE), attending the Transfusion Medicine or the Rheumatology Clinic at the Policlinico Tor Vergata, Rome, Italy, were tested for Tα1 content by means of a commercial enzyme-linked immunosorbent assay (ELISA) kit. Data were analysed in relation to demographic and clinical characteristics of patients and controls. A gender difference was found in the HC group, where females had lower serum Tα1 levels than males (P < 0·0001). Patients had lower serum Tα1 levels than HC (P < 0·0001), the lowest were observed in PsA group (P < 0·0001 versus all the other groups). Among all patients, those who at the time of blood collection were taking disease-modifying anti-rheumatic drugs (DMARD) plus steroids had significantly higher Tα1 levels than those taking DMARD alone (P = 0·044) or no treatment (P < 0·0001), but not of those taking steroids alone (P = 0·280). However, whichever type of treatment was taken by the patients, serum Tα1 was still significantly lower than in HC and there was no treatment-related difference in PsA group. Further prospective studies are necessary to confirm and deepen these observations. They might improve our understanding on the regulatory role of Tα1 in health and disease and increase our knowledge of the pathogenesis of chronic inflammatory autoimmune diseases.

show abstract

Section: Discussionmentioning

confidence: 72%

Serum thymosin α 1 levels in patients with chronic inflammatory autoimmune diseases

Pica¹,

Chimenti

Gaziano³

et al. 2016

Clinical and Experimental Immunology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Histologically, PsA is characterized by lining layer hyperplasia, B and T lymphocytes' infiltrates, innate immune cells' activation, and joint vascular remodeling and angiogenesis [165]. We previously reported an abnormal distribution of peripheral blood B cell in both RA and PsA patients suggesting a role of B cells in PsA pathogenesis [166]. An autoimmune model describing potential autoantigens in the skin and joints of PsA patients has not been identified so far [151].…”

Section: Autoantibodies In Psoriatic Arthritismentioning

confidence: 99%

Autoantibodies in inflammatory arthritis

Conigliaro

Chimenti

Triggianese

et al. 2016

Autoimmunity Reviews

100

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is a systemic chronic inflammatory disease characterized by extensive synovitis resulting in erosions of articular cartilage and marginal bone with joint destruction. The lack of immunological tolerance in RA represents the first step toward the development of autoimmunity. Susceptible individuals, under the influence of environmental factors, such as tobacco smoke, and silica exposure, develop autoimmune phenomena that result in the presence of autoantibodies. HLA and non-HLA haplotypes play a major role in determining the development of specific autoantibodies differentiating anti-citrullinated antibodies (ACPA)-positive and negative RA patients. Rheumatoid factor (RF) and ACPA are the serological markers for RA, and during the preclinical immunological phase, autoantibody titers increase with a progressive spread of ACPA antigens repertoire. The presence of ACPA represents an independent risk factor for developing RA in patients with undifferentiated arthritis or arthralgia. Moreover, anti-CarP antibodies have been identified in patients with RA as well as in individuals before the onset of clinical symptoms of RA. Several autoantibodies mainly targeting post-translational modified proteins have been investigated as possible biomarkers to improve the early diagnosis, prognosis and response to therapy in RA patients. Psoriatic arthritis (PsA) is distinguished from RA by infrequent positivity for RF and ACPA, together with other distinctive clinical features. Actually, specific autoantibodies have not been described. Recently, anti-CarP antibodies have been reported in sera from PsA patients with active disease. Further investigations on autoantibodies showing high specificity and sensibility as well as relevant correlation with disease severity, progression, and response to therapy are awaited in inflammatory arthritides

show abstract

“…Several lines of evidence in the literature demonstrated that ADA and ETN exert a different effect on innate and adaptive immune cell population in RA treated patients despite their similar effectiveness [42–44]. Our preliminary data seems to suggest that the associations may be drug specific.…”

Section: Discussionmentioning

confidence: 54%

Polymorphisms in STAT4, PTPN2, PSORS1C1 and TRAF3IP2 Genes Are Associated with the Response to TNF Inhibitors in Patients with Rheumatoid Arthritis

et al. 2017

View full text Add to dashboard Cite

ObjectiveRheumatoid Arthritis (RA) is a progressive autoimmune disease characterized by chronic joint inflammation and structural damage. Remission or at least low disease activity (LDA) represent potentially desirable goals of RA treatment. Single nucleotide polymorphisms (SNPs) in several genes might be useful for prediction of response to therapy. We aimed at exploring 4 SNPs in candidate genes (STAT4, PTPN2, PSORS1C1 and TRAF3IP2) in order to investigate their potential role in the response to therapy with tumor necrosis factor inhibitors (TNF-i) in RA patients.MethodsIn 171 RA patients we investigated the following SNPs: rs7574865 (STAT4), rs2233945 (PSORS1C1), rs7234029 (PTPN2) and rs33980500 (TRAF3IP2). Remission, LDA, and EULAR response were registered at 6 months and 2 years after initiation of first line TNF-i [Adalimumab (ADA) and Etanercept (ETN)].ResultsSTAT4 variant allele was associated with the absence of a good/moderate EULAR response at 2 years of treatment in the whole RA group and in ETN treated patients. The PTPN2 SNP was associated with no good/moderate EULAR response at 6 months in ADA treated patients. Patients carrying PSORS1C1 variant allele did not reach LDA at 6 months in both the whole RA group and ETN treated patients. TRAF3IP2 variant allele was associated with the lack of LDA and remission achievement at 6 months in all RA cohort while an association with no EULAR response at 2 years of treatment occurred only in ETN treated patients.ConclusionsFor the first time, we reported that SNPs in STAT4, PTPN2, PSORS1C1, and TRAF3IP2 are associated with response to TNF-i treatment in RA patients; however, these findings should be validated in a larger population.

show abstract

Restoration of peripheral blood natural killer and B cell levels in patients affected by rheumatoid and psoriatic arthritis during etanercept treatment

Cited by 49 publications

References 46 publications

Serum thymosin α 1 levels in patients with chronic inflammatory autoimmune diseases

Serum thymosin α 1 levels in patients with chronic inflammatory autoimmune diseases

Autoantibodies in inflammatory arthritis

Polymorphisms in STAT4, PTPN2, PSORS1C1 and TRAF3IP2 Genes Are Associated with the Response to TNF Inhibitors in Patients with Rheumatoid Arthritis

Contact Info

Product

Resources

About